4/A: MAIA CEO Corrects Insider Stock Holdings

MAIA Biotechnology's CEO, Vlad Vitoc, filed an amended Form 4 to correct previously reported direct and indirect beneficial ownership of common stock.

Summary

• Vlad Vitoc, CEO, Director, and 10% Owner of MAIA Biotechnology, Inc., filed an amended Form 4 (Form 4/A) on December 3, 2025.
• The amendment corrects the total share balance beneficially owned by Mr. Vitoc and his spouse, which was incorrectly reported in the original Form 4 filed on December 1, 2025.
• On November 26, 2025, Mr. Vitoc purchased 22,000 shares of common stock at a weighted average price of $1.0463 per share.
• On November 28, 2025, Mr. Vitoc purchased an additional 50,000 shares of common stock at a weighted average price of $1.1366 per share.
• Following these transactions, Mr. Vitoc directly beneficially owns 903,421 shares.
• An additional 210,100 shares are indirectly beneficially owned by Mr. Vitoc's spouse.

Sentiment

Score: 6

Explanation: The insider buying by the CEO is a positive signal of confidence. However, the need for an amendment due to incorrect reporting introduces a minor administrative negative, slightly tempering the overall positive sentiment from the buying activity.

Positives

• CEO Vlad Vitoc purchased a total of 72,000 shares of common stock in open market transactions, indicating confidence in the company's future prospects.
• The purchases were made at weighted average prices of $1.0463 and $1.1366, representing a direct investment by management.

Negatives

• An error in the original Form 4 filing regarding the total share balance for both the CEO and his spouse required an amendment, which could suggest minor administrative oversight in reporting.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
• The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Industry Context

This filing details an insider transaction and correction, which is specific to MAIA Biotechnology and its CEO. It does not provide information directly related to broader industry trends or competitive landscape.

Comparison to Industry Standards

• This filing is a standard insider transaction report (Form 4/A) and does not contain information suitable for comparison to industry-specific project results or company performance benchmarks.

Related Party Transactions

• Mr. Vitoc's spouse indirectly beneficially owns 210,100 shares, which are disclosed as related party holdings, with Mr. Vitoc disclaiming beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The CEO's open market purchases could be viewed positively as a sign of management confidence, potentially influencing investor sentiment. The correction of previously misreported holdings ensures accurate disclosure for shareholders.
• Regulatory Authorities: The amendment demonstrates compliance with SEC reporting requirements by correcting previously filed information.

Next Steps

• No specific future actions or milestones are mentioned beyond the standard undertaking to provide detailed transaction information upon request.

Key Dates

Recommendation

The insider buying by the CEO is a positive indicator of confidence, suggesting potential upside. However, the filing is purely transactional and corrective, lacking broader financial or operational updates. Without additional context on the company's performance, strategy, or market conditions, a 'hold' recommendation is prudent, acknowledging the positive insider action while awaiting more comprehensive information for a stronger stance.

Keywords

MAIA Biotechnology, MAIA, Vlad Vitoc, Insider Trading, Form 4/A, Stock Purchase, CEO, Director, 10% Owner, Beneficial Ownership, SEC Filing